ATTAIN STUDY ACLIDINIUM PDF

The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD). David Singh, Eric D. Bateman, Paul W. Jones. The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease. Eric D. Bateman, David Singh, Paul W. Jones, Alvar. This paper presents results from a phase III study of longer duration (Aclidinium To Treat Airway obstruction In COPD patieNts; ATTAIN), which.

Author: Kihn Fenrigis
Country: Spain
Language: English (Spanish)
Genre: Life
Published (Last): 20 February 2015
Pages: 115
PDF File Size: 4.74 Mb
ePub File Size: 2.52 Mb
ISBN: 608-1-88636-794-6
Downloads: 9430
Price: Free* [*Free Regsitration Required]
Uploader: Gagal

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.

In the pivotal Phase III clinical trials, patients receiving aclidinium achieved significantly greater improvements in lung function, reductions in breathlessness, and improvements in health status compared with placebo, for up to 24 weeks.

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. The author and his institution have received consulting and lecture fees from Almirall S.

Reproduced with permission of Informa Healthcare. Significant improvements were seen in breathlessness, health status, and COPD symptoms in the pivotal trials.

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease

In the ACCORD COPD I study, 31 night-time and morning COPD symptoms were all significantly reduced among patients treated with aclidinium compared with those who received placebo Figure 5and the impact of breathlessness on early morning activities was also significantly reduced with aclidinium versus placebo Figure adlidinium.

There were no statistically significant differences between the two aclidinium arms. A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD.

  AKG DSR 700 PDF

Reduced COPD exacerbations associated with aclidinium bromide versus placebo: Tiotropium versus placebo for chronic obstructive pulmonary disease.

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.

It has been extensively studied in patients with COPD — a recent Cochrane review identified 22 studies of good methodological quality that had enrolled 23, participants with COPD. Twice-daily aclidinium bromide in COPD patients: However, the rate aclidiniim decline in FEV 1 — the primary outcome of the trial — was not significantly reduced by the use of tiotropium. Preference, satisfaction and errors with two dry powder inhalers in patients with COPD.

Week 12 trough FEV 1 change from baseline vs placebo: Data reported as least squares mean standard error. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting beta-agonist therapy in COPD.

COPD Efficacy Study | TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder)

Prior to peer review, Almirall S. In conclusion, when considering new inhaled drugs, it is important to look beyond the chemical entity and its pharmacology. Aclidinium bromide provides long-acting bronchodilation in patients with Attajn. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. Phase II Joos et al Author information Copyright and License information Disclaimer.

This article has been cited by other articles in PMC. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.

The subject of this review is a third LAMA, aclidinium bromide, which was approved as a twice-daily maintenance bronchodilator treatment. Safety and tolerability of aclidinium bromide in patients with COPD: The BID dosing does not appear to be a disadvantage compared sthdy the QD regimes of tiotropium and glycopyrronium, since it may confer better overnight bronchodilation that may be particularly beneficial for patients with significant night and morning symptoms.

  GONZALO HALFFTER PDF

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease

Discussion As noted in the current GOLD guidelines, tiotropium, aclidinium, and glycopyrronium can all be considered as appropriate options for maintenance treatment in the stable COPD patient.

Open in a separate window. Eur Respir JOctober Aclidinium has been extensively evaluated in patients with COPD Table 1 29 — 39 and has also been the subject of a recent Cochrane atfain review.

Breathlessness, health status, and COPD symptoms with aclidinium Significant improvements were seen in breathlessness, health status, and COPD symptoms in the pivotal trials.

Food and Drug Administration Tudorza Pressair: Again, these benefits were seen from the first dose until the end of the study Figure 3B. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: Pharmacokinetic sthdy in healthy volunteers showed that it is poorly absorbed into plasma and rapidly hydrolyzed into two major inactive stuudy, resulting in limited systemic exposure.

Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: The three LAMAs also provide patients with a choice, as each is delivered by a different device, and some patients may prefer one over another.

The safety profile of aclidinium was comparable to placebo.